GILD Share Price

Open 71.97 Change Price %
High 72.00 1 Day -0.56 -0.78
Low 70.58 1 Week -2.06 -2.82
Close 71.01 1 Month -2.63 -3.57
Volume 10270332 1 Year -20.82 -22.67
52 Week High 103.10
52 Week Low 70.58
GILD Important Levels
Resistance 2 72.33
Resistance 1 71.78
Pivot 71.20
Support 1 70.24
Support 2 69.69
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 5
As on 20th Jan 2017 GILD Share Price closed @ 71.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 82.10 & Strong Sell for SHORT-TERM with Stoploss of 74.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.